Keyphrases
Venous Thromboembolism
100%
Multiple Myeloma
94%
Chronic Liver Disease
94%
Hemorrhage Risk
67%
Anticoagulant Therapy
62%
Bleeding
56%
Anticoagulation
53%
Increased Mortality
53%
Hospitalization
52%
University of Washington
47%
Coagulation Profile
47%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
47%
Splanchnic Vein Thrombosis
47%
Clinical Investigator
47%
Abiraterone
47%
Enzalutamide
47%
Direct Oral Anticoagulants
47%
Pulmonary Embolism
47%
Cirrhosis
47%
Deep Vein Thrombosis
47%
Population-based
47%
Graft-versus-host Disease (GvHD)
47%
Warfarin Therapy
47%
Statins
47%
International Normalized Ratio
47%
Resectable Pancreatic Cancer
47%
Population-based Retrospective Cohort Study
47%
Philadelphia-negative Myeloproliferative Neoplasms
47%
Hematological Cancer
47%
Cancer-associated Venous Thromboembolism
47%
Patients with Hematological Malignancies
47%
Malignancy-associated
47%
Anticoagulants
47%
Confidence Interval
40%
Primary Myelofibrosis
37%
Essential Thrombocythemia
37%
Prognostic Factors
33%
Warfarin
32%
Isocitrate Dehydrogenase 1 (IDH1)
28%
Polycythemia Vera
28%
Adjusted Hazard Ratio
27%
Androgen Receptor Antagonist
25%
Hematologist
23%
Evidence-based Guidelines
23%
Transfusion Medicine
23%
Young Female
23%
Clinical Effect
23%
Department of Medicine
23%
Health Outcomes
23%
Coagulation Factors
23%
Medicine and Dentistry
Venous Thromboembolism
94%
Bleeding
83%
Anticoagulant Therapy
62%
Prognostic Factor
52%
Direct Oral Anticoagulant
47%
Liver Cirrhosis
47%
Deep Vein Thrombosis
47%
Pulmonary Embolism
47%
Multiple Myeloma
47%
Myeloproliferative Neoplasm
47%
Prognostication
47%
Phlebothrombosis
47%
Pancreas Cancer
47%
Philadelphia 1 Chromosome
47%
Hematologic Malignancy
47%
Hematological Cancer
47%
Antithrombotic
47%
Myeloid metaplasia
37%
Essential Thrombocythaemia
37%
Proportional Hazards Model
30%
Anticoagulation
30%
Polycythemia vera
28%
Thrombosis
25%
Portal Hypertension
23%
Platelet
23%
Nonalcoholic Fatty Liver
23%
Child-Pugh Score
23%
Hepatic Encephalopathy
23%
Thrombocytopenia
23%
Partial Thromboplastin Time
23%
Prothrombin Time
23%
Fibrinogen
23%
Esophageal Varices
23%
Myelofibrosis
18%
ASXL1
18%
Hazard Ratio
15%
Lenalidomide
15%
Pancreas Adenocarcinoma
13%
International Classification of Diseases
12%
Veterans Health
11%
Gastrointestinal Bleeding
11%
Cerebral Hemorrhage
11%
Myeloma
10%
Chromosome Aberration
9%
Janus Kinase
9%
Hydroxyurea
9%
Phlebotomy
9%
Leukocytosis
9%
Prospective Study
9%
Risk Stratification
9%